Please ensure Javascript is enabled for purposes of website accessibility

The Most Important of Moderna's 3 Catalysts Last Week

By Keith Speights and Brian Orelli, PhD - Updated Jun 25, 2021 at 1:46PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Moderna stock has been on a roll for several reasons.

Moderna (MRNA 3.27%) has been quite busy. The company announced three positive developments last week, all of which have the potential to boost sales for its COVID-19 vaccine. In this Motley Fool Live video recorded on June 9, Motley Fool contributors Keith Speights and Brian Orelli discuss which of these is the most important catalyst for the biotech stock.

Keith Speights: Brian, we were asked on Monday at the tail end of the segment, what's going on with Moderna? Moderna has actually been on a roll this week.

The company had three different announcements on Monday. It filed for a conditional approval of its COVID-19 vaccine and treating adolescents with the European Union. It filed for a similar authorization in Canada. Then third, the company announced a partnership with Medicine Pharma to market its COVID-19 vaccine throughout Central Eastern Europe and Israel.

Which of these do you think is the most important catalyst for Moderna?

Brian Orelli: They're all incrementally important. I didn't find any stats on populations for adolescents. But if you look at the population for all children, the EU population is substantially larger than Canada. If we're just comparing those two obviously filing in the EU, is much more important than filing in Canada for that reason alone.

The deal with Medicine Pharma didn't have any financial details so we don't know how much Moderna is giving up, probably as a royalty to Medicine to market it.

But nevertheless, I like the idea. It makes sense because setting up its own commercial organization there will be quite challenging, and take a lot of effort. I guess of the three the medicine deal makes most sense with the caveat that we don't actually know enough of the details to know how much they're giving up in terms of financing.

Brian Orelli, PhD has no position in any of the stocks mentioned. Keith Speights has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Moderna, Inc. Stock Quote
Moderna, Inc.
MRNA
$176.78 (3.27%) $5.60

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/15/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.